Nuvation Bio Inc. (NYSE:NUVB) Stock Holdings Boosted by GSA Capital Partners LLP

GSA Capital Partners LLP boosted its holdings in shares of Nuvation Bio Inc. (NYSE:NUVB - Free Report) by 172.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 661,052 shares of the company's stock after acquiring an additional 418,799 shares during the period. GSA Capital Partners LLP owned about 0.20% of Nuvation Bio worth $1,163,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC acquired a new position in Nuvation Bio during the fourth quarter worth about $27,000. BNP Paribas Financial Markets purchased a new stake in shares of Nuvation Bio during the fourth quarter worth about $64,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Nuvation Bio by 54.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 347,806 shares of the company's stock worth $925,000 after buying an additional 122,187 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Nuvation Bio by 82.7% during the fourth quarter. Millennium Management LLC now owns 2,475,872 shares of the company's stock worth $6,586,000 after buying an additional 1,120,874 shares in the last quarter. Finally, California State Teachers Retirement System grew its holdings in shares of Nuvation Bio by 40.1% during the fourth quarter. California State Teachers Retirement System now owns 200,380 shares of the company's stock worth $533,000 after buying an additional 57,310 shares in the last quarter. Institutional investors and hedge funds own 61.67% of the company's stock.

Nuvation Bio Stock Down 5.9%

Shares of NYSE NUVB traded down $0.14 during trading on Friday, reaching $2.22. 3,600,421 shares of the stock were exchanged, compared to its average volume of 4,895,160. The business's 50-day moving average price is $2.19 and its 200 day moving average price is $2.15. Nuvation Bio Inc. has a twelve month low of $1.54 and a twelve month high of $3.45. The company has a market capitalization of $755.38 million, a price-to-earnings ratio of -0.94 and a beta of 1.35.

Nuvation Bio (NYSE:NUVB - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16). The firm had revenue of $3.08 million for the quarter, compared to analysts' expectations of $0.42 million. Nuvation Bio had a negative net margin of 5,534.21% and a negative return on equity of 44.14%. As a group, sell-side analysts expect that Nuvation Bio Inc. will post -0.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

NUVB has been the subject of a number of recent research reports. Citigroup initiated coverage on shares of Nuvation Bio in a report on Wednesday, April 23rd. They set an "outperform" rating for the company. Wall Street Zen upgraded shares of Nuvation Bio from a "sell" rating to a "hold" rating in a report on Saturday, July 26th. Citizens Jmp initiated coverage on shares of Nuvation Bio in a report on Wednesday, April 23rd. They set a "mkt outperform" rating and a $6.00 price target for the company. JMP Securities restated a "market outperform" rating and issued a $6.00 target price on shares of Nuvation Bio in a report on Wednesday, June 25th. Finally, Wedbush restated an "outperform" rating and issued a $5.00 target price on shares of Nuvation Bio in a report on Wednesday, June 11th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $7.17.

Nuvation Bio Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.